Literature DB >> 6188812

Long-term experience with bromocriptine in advanced parkinsonism. Results after one year's treatment.

E Schneider, P A Fischer.   

Abstract

The long-term effects of bromocriptine as an adjuvant were investigated in 32 patients (20 male, 12 female), aged 43-76 years (mean 65.4), suffering from parkinsonism for 3-20 years (mean 9.3). Patients were pretreated with levodopa/decarboxylase inhibitor for 24-116 months (mean 74.9). Bromocriptine was given because of a decline in the response to levodopa, various kinds of "on-off" phenomena, and disabling dyskinesias. Levodopa was reduced by 18%, while bromocriptine was added with a mean dose of 29 mg. The results showed a marked tremor and rigidity response, clearly greater than that of bradykinesia of the hands. The improvement after 4 weeks of bromocriptine treatment was maintained over 12 months. Only gait disturbances tended to increase. At the same time the self-ratings of the patients showed an increase in disability as far as daily activities were concerned. Likewise, the "on-off" symptoms with regard to the wearing-off effects worsened in comparison with the condition during the 4-week period. Akinesia paradoxica was never definitely influenced. An increase in dyskinesias was avoided and serious side-effects could be kept under control.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6188812     DOI: 10.1007/bf00313415

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  The choreoathetoid movement disorder induced by levodopa.

Authors:  C H Markham
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

2.  The antiparkinsonian efficacy of bromocriptine.

Authors:  A Lieberman; M Zolfaghari; D Boal; H Hassouri; B Vogel; A Battista; K Fuxe; M Goldstein
Journal:  Neurology       Date:  1976-05       Impact factor: 9.910

3.  [Clinical experience with bromocriptine, a central dopaminergic stimulator].

Authors:  H P Ludin; F Kunz; P Lörincz; E Ringwald
Journal:  Nervenarzt       Date:  1976-11       Impact factor: 1.214

4.  [Bromocriptin in the treatment of progressive stages of Parkinson's disease (author's transl)].

Authors:  E Schneider; P A Fischer
Journal:  Dtsch Med Wochenschr       Date:  1982-02-05       Impact factor: 0.628

5.  Bromocriptine in Parkinson's disease.

Authors:  K M Shaw; A J Lees; G M Stern
Journal:  Lancet       Date:  1978-06-10       Impact factor: 79.321

6.  [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].

Authors:  Y Agid; N Quinn; F Lhermitte
Journal:  Rev Neurol (Paris)       Date:  1981       Impact factor: 2.607

7.  Bromocriptine in Parkinson disease: further studies.

Authors:  A N Lieberman; M Kupersmith; G Gopinathan; E Estey; A Goodgold; M Goldstein
Journal:  Neurology       Date:  1979-03       Impact factor: 9.910

Review 8.  Bromocriptine in Parkinsonism.

Authors:  I Pearce; J M Pearce
Journal:  Br Med J       Date:  1978-05-27

9.  Long-term efficacy of bromocriptine in Parkinson disease.

Authors:  A Lieberman; M Kupersmith; A Neophytides; I Casson; R Durso; S H Foo; M Khayali; G Bear; M Goldstein
Journal:  Neurology       Date:  1980-05       Impact factor: 9.910

10.  Long-term treatment of Parkinson's disease with bromocriptine.

Authors:  A Rascol; B Guiraud; J L Montastruc; J David; M Clanet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-02       Impact factor: 10.154

View more
  2 in total

1.  Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.

Authors:  H Baas; E Schneider; P A Fischer; G Japp
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

2.  Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.

Authors:  E Schneider; H Baas; P A Fischer; G Japp
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.